Cargando…

Management of adrenocortical carcinoma: are we making progress?

Adrenocortical carcinoma (ACC) is a rare malignancy characterized by aggressive biology and potential endocrine activity. Surgery can offer cure for localized disease but more than half of patients relapse and primary unresectable or metastasized disease is frequent. Prognosis of metastatic ACC is s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kiesewetter, Barbara, Riss, Philipp, Scheuba, Christian, Mazal, Peter, Kretschmer-Chott, Elisabeth, Haug, Alexander, Raderer, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411624/ https://www.ncbi.nlm.nih.gov/pubmed/34484430 http://dx.doi.org/10.1177/17588359211038409

Ejemplares similares

Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna
por: Melhorn, Philipp, et al.
Publicado: (2022)

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
por: Kiesewetter, B., et al.
Publicado: (2022)

How I treat medullary thyroid cancer
por: Kiesewetter, B., et al.
Publicado: (2021)

Corrigendum to ‘How I treat medullary thyroid cancer’: [ESMO Open Volume 6, Issue 3, June 2021, 100183]
por: Kiesewetter, B., et al.
Publicado: (2022)

Accessing the influence of (99m)Tc-Sesta-MIBI-positive thyroid nodules on preoperative localisation studies in patients with primary hyperparathyroidism
por: Hargitai, Lindsay, et al.
Publicado: (2022)

My burning issues in neuroendocrine tumours (NET)
por: Kiesewetter, Barbara, et al.
Publicado: (2018)

How I treat MALT lymphoma: ‘a subjective interpretation of the gospel according to Isaacson….’
por: Raderer, Markus, et al.
Publicado: (2020)

How I treat neuroendocrine tumours
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

What you always wanted to know about gastric MALT-lymphoma: a focus on recent developments
por: Raderer, Markus, et al.
Publicado: (2021)

Papillary thyroid cancer: the value of bilateral diagnostic lymphadenectomy
por: Bhangu, Jagdeep Singh, et al.
Publicado: (2022)

Prophylactic “First-Step” Central Neck Dissection (Level 6) Does Not Increase Morbidity After (Total) Thyroidectomy
por: Selberherr, Andreas, et al.
Publicado: (2016)

Endokrine und neuroendokrine Tumoren
por: Riss, Philipp, et al.
Publicado: (2021)

Infection with multidrug-resistant Campylobacter coli mimicking recurrence of carcinoid syndrome: a case report of a neuroendocrine tumor patient with repeated diarrhea
por: Lagler, Heimo, et al.
Publicado: (2016)

Is there a reliable size cut-off for splenic involvement in lymphoma? A [18F]FDG-PET controlled study
por: Berzaczy, Dominik, et al.
Publicado: (2019)

First Line Systemic Treatment for MALT Lymphoma—Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal
por: Raderer, Markus, et al.
Publicado: (2023)

Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients
por: Berzaczy, Dominik, et al.
Publicado: (2019)

How radical is total parathyroidectomy in patients with renal hyperparathyroidism?
por: Burgstaller, Thomas, et al.
Publicado: (2018)

Applicability of a shortened interpretation model for intraoperative parathyroid hormone monitoring in patients with primary hyperparathyroidism in an endemic goiter region
por: Riss, Philipp, et al.
Publicado: (2018)

“Silent” kidney stones in “asymptomatic” primary hyperparathyroidism—a comparison of multidetector computed tomography and ultrasound
por: Selberherr, Andreas, et al.
Publicado: (2016)

Clinical outcome of standardized (177)Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks
por: Rasul, Sazan, et al.
Publicado: (2019)

Medullary Thyroid Carcinoma: Do Ultrasonography and F-DOPA-PET-CT Influence the Initial Surgical Strategy?
por: Brammen, Lindsay, et al.
Publicado: (2018)

Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?
por: Srougi, Victor, et al.
Publicado: (2017)

Adrenocortical Carcinoma
por: Berruti, Alfredo, et al.
Publicado: (2021)

Neuroendocrine liver metastasis from the small intestine: Is surgery beneficial for survival?
por: Selberherr, Andreas, et al.
Publicado: (2021)

The value of intraoperative parathyroid hormone monitoring in patients with primary hyperparathyroidism and varying baseline parathyroid hormone levels
por: Hargitai, Lindsay, et al.
Publicado: (2022)

Successful Clarithromycin Monotherapy in a Patient with Primary Follicular Lymphoma of the Duodenum
por: Kiesewetter, Barbara, et al.
Publicado: (2018)

Prediction of response and survival after standardized treatment with 7400 MBq (177)Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer
por: Rasul, Sazan, et al.
Publicado: (2020)

Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression
por: Xu, Yunze, et al.
Publicado: (2015)

PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations
por: Mayerhoefer, Marius E., et al.
Publicado: (2019)

Mitotane in adrenocortical carcinoma.
por: Vassilopoulou-Sellin, R., et al.
Publicado: (1994)

Pediatric adrenocortical carcinoma
por: Ilanchezhian, Maran, et al.
Publicado: (2022)

Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [(68)Ga]Ga-Pentixafor-PET/MRI
por: Haug, Alexander R., et al.
Publicado: (2019)

Intertumor heterogeneity in 60 pancreatic neuroendocrine tumors associated with multiple endocrine neoplasia type 1
por: Selberherr, Andreas, et al.
Publicado: (2019)

FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma
por: Tamburello, Mariangela, et al.
Publicado: (2022)

CXCR4 PET imaging of mantle cell lymphoma using [(68)Ga]Pentixafor: comparison with [(18)F]FDG-PET
por: Mayerhoefer, Marius E., et al.
Publicado: (2021)

Ultra-early response assessment in lymphoma treatment: [(18)F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment
por: Mayerhoefer, Marius E., et al.
Publicado: (2018)

Prolonged follow‐up on lenalidomide‐based treatment for mucosa‐associated lymphoid tissue lymphoma (MALT lymphoma)—Real‐world data from the Medical University of Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2019)

Calcium-stimulated calcitonin - The “new standard” in the diagnosis of thyroid C-cell disease - clinically relevant gender-specific cut-off levels for an “old test”
por: Niederle, Martin B., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q8ud9qqnfp2viqih2fa0ngptbh